REIMAGINE 2 was a 68-week efficacy and safety phase 3 trial of CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg once-weekly versus semaglutide 2.4 mg, semaglutide 1 mg, cagrilintide 2.4 mg, and placebo in 2,713 adults with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor
FDA-APPROVED INDICATIONS Injection Weight loss (adults) As an adjunct to diet and exercise for weight loss in adults with a BMI 30 or 27 in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes, dyslipidemia) [STEP 1 study] Adult BMI calculator Weight loss (children 12 years old) As an adjunct to a reduced-calorie diet and increased physical activity in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex
In the context of neurodegeneration, this may help stabilize neuronal energy production when glucose uptake and utilization are compromised
doi: 10.1016/j.bbaexp.2005.02.003 161 YangW
Meet Your Weight Loss Provider Semaglutide treatment at Forward Healthy Lifestyles is overseen by Lindsay Carmody, MSN, FNP-BC, APNP